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a  b  s  t  r  a  c  t
In  the  last  decade,  carbapenem-resistant  Klebsiella  pneumoniae  (CR-Kp)  has  become  endemic  in  several
countries,  including  Italy.  In  the  present  study,  we  assessed  the differences  in  epidemiology,  management,
and  mortality  of  CR-Kp  bloodstream  infection  (BSI)  in the  three  main  adult  acute-care  hospitals  of  the
metropolitan  area  of  Genoa,  Italy.
From January  2013  to December  2014,  all patients  with  CR-Kp  BSI were  identified  through  the com-
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puterized  microbiology  laboratory  databases  of the  three  hospitals.  The  primary  endpoints  of  the  studyPlease cite this article in press as: Cristina ML,  et al. Epidemiology, management, and outcome of carbapenem-resistant Kleb-







were  incidence  and  characteristics  of  CR-Kp  BSI in hospitals  within  the same  endemic  metropolitan  area.
Secondary  endpoints  were  characteristics  of  CR-Kp  BSI  in hospitals  with  and  without  internal  infectious
diseases  consultants  (IDCs)  and  15-day  mortality.
During  the  study  period,  the  incidence  of healthcare-associated  CR-Kp  BSI  in the  entire  study  population
was  1.35  episodes  per 10,000  patient-days,  with  substantial  differences  between  the three  hospitals.
Abbreviations: CR-Kp, carbapenem-resistant Klebsiella pneumoniae; BSI, bloodstream infections; ID, infectious diseases; LHU, Local Health Unit; COPD, chronic obstructive
ulmonary disease; CVC, central venous catheter; MICs, minimum inhibitory concentrations; EUCAST, European Committee on Antimicrobial Susceptibility Testing; 95% CI,
5%  confidence intervals; IQR, interquartile range; ICU, intensive care unit; OR, odds ratio.
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Patients  admitted  to the  two  hospital  with  internal  IDCs  were  more  likely  to  receive  post-susceptibility
test  combined  therapy  including  carbapenems  (77%  vs.  26%,  p < 0.001),  adequate  post-susceptibility  test
therapies  (86%  vs. 52%,  p < 0.001),  and post-susceptibility  therapies  prescribed  by an  infectious  diseases
specialist  (84%  vs.  14%,  p <  0.001).  Overall,  the crude  15-days  mortality  was 26%.  In the  final  multivariable
model,  only  septic  shock  at BSI  presentation  was  unfavorably  and  independently  associated  with  15-days
mortality  (odds  ratio  [OR]  6.7,  95%  confidence  intervals  [CI]  2.6–17.6,  p  <  0.001),  while  a protective  effect
was observed  for post-susceptibility  test  combined  therapies  including  a carbapenem  (OR  0.11,  95%  CI
0.03–0.43,  p  =  0.002).
Mortality  of CR-Kp  remains  high.  Differences  in the  incidence  of  CR-Kp  BSI  were detected  between
acute-care  centers  within  the  same  endemic  metropolitan  area. Efforts  should  be made  to improve  the
collaboration  and  coordination  between  centers,  to prevent  further  diffusion  of  CR-Kp.









































Health  Sciences.  This  is  an
ntroduction
In the last decade, carbapenem-resistant Klebsiella pneumo-
iae (CR-Kp) has become endemic in several countries, including
taly, and outbreaks of bloodstream infections (BSI) caused by this
athogen continue to be increasingly reported worldwide [1–13].
CR-Kp BSI are associated with high mortality, mostly because
f the paucity of antimicrobials active against CR-Kp and the fre-
uent heavy burden of comorbidities in patients developing the
isease [14–18]. However, most information regarding treatment
trategies, outcomes, and characteristics of patients with CR-Kp BSI
erives from multicentre observational studies conducted in large
ospitals in different cities, while multicentre data from a same
etropolitan area remain scant [10,17,18]. In this regard, possible
ifferences in the characteristics, management, and outcomes of
atients within neighboring centers might help identifying aspects
o be specifically addressed for improving care locally.
In the present study, we assessed the differences in epidemi-
logy, management, and mortality of CR-Kp BSI in three large
ospitals in Genoa, Italy.
aterial and methods
tudy design and setting
A multicenter retrospective study was conducted in the three
ain adult acute-care public hospitals of the metropolitan area of
enoa, Northern Italy: IRCCS AOU San Martino – IST, a 1300-beds
dult acute-care tertiary teaching hospital (hospital A); Galliera
ospital, a 450-beds adult acute-care tertiary non-teaching hos-
ital (hospital B); Local Health Unit (LHU) hospital, a 630-beds
dult acute-care secondary non-teaching hospital (hospital C). The
umber of intensive care unit (ICU) beds in the three centers is
s follows: 55 (hospital A); 10 (hospital B); 28 (hospital C). Of note,
ospitals A and B have their own internal senior infectious diseases
onsultants (IDCs), while hospital C relies on external consultations.
ore specifically, external consultations are conducted at the bed-
ide upon request, by senior infectious diseases specialists from
ospital A.
From January 2013 to December 2014, all patients with CR-Kp
SI were identified through the computerized microbiology labo-
atory databases of the three hospitals. Only health-care associated
R-Kp BSI were considered for the analysis, according to the def-
nition of the European Center for Disease Control and preventionPlease cite this article in press as: Cristina ML,  et al. Epidemiolo
siella pneumoniae bloodstream infections in hospitals within the sa
http://dx.doi.org/10.1016/j.jiph.2017.06.003
19]. Briefly, CR-Kp BSI was defined as a positive blood culture
ollected at least 48 h after hospital admission, or within 48 h from
ospital admission in those patients who had been discharged
n the preceding two days. For patients with multiple episodesn  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
of CR-Kp BSI, a novel event was  considered as independent if
occurring at least 30 days after the last positive blood culture [19].
The primary endpoint of the study was  incidence of CR-Kp BSI in
the overall metropolitan area of Genoa. Secondary endpoints were
characteristics of CR-Kp BSI in hospitals with and without internal
IDCs and 15-day mortality. For transparency, information on the
incidence of Cr-Kp BSI in the hospital A (but not the characteristics
of the episodes) was already included in a previous study [4].
The study involved the analysis of existing anonymized clinical
and laboratory data. An informed consent for the use of anonymized
data for scientific purposes is signed by all patients admitted to
the three adult acute-care hospitals and included in surveillance
databases. The study was  approved by the Regional Ethics Com-
mittee of Liguria Region.
Data collection
The following demographic and clinical data were collected:
age, gender, Charlson score (i.e., a cumulative score summarizing
different categories of comorbidity, with higher scores indicating
a greater burden of baseline comorbid conditions [20]), chronic
obstructive pulmonary disease (COPD), chronic renal failure, solid
neoplasm, hematologic malignancy, diabetes mellitus, previous
surgery, ward of stay at the time of CR-Kp BSI, time from hospi-
tal admission to CR-Kp BSI, presence of a central venous catheter
(CVC), presence of mechanical ventilation, clinical presentation as
septic shock (i.e., presence of organ dysfunction and persistent
hypotension despite volume replacement [21]), type and adequate-
ness of initial and post-susceptibility test antimicrobial therapy (an
antimicrobial therapy was defined as adequate if including at least
one drug showing in vitro activity against the CR-Kp isolate), post-
susceptibility test therapy prescribed by IDCs (yes vs no), 15-day
crude mortality.
Microbiology
The Vitek 2 system (bioMérieux, Marcy l’Etoile, France) was
used for the identification of Kp and for antimicrobial suscep-
tibility testing. Carbapenem minimum inhibitory concentrations
(MICs) were classified as carbapenem-susceptible or resistant
according to the European Committee on Antimicrobial Suscep-
tibility Testing (EUCAST) breakpoints (EUCAST breakpoint tables
for interpretation of MICs and zone diameters, version 6.0, 2016;gy, management, and outcome of carbapenem-resistant Kleb-
me endemic metropolitan area. J Infect Public Health (2017),
http://www.eucast.org). For the analysis, Kp isolates which were
resistant to one or more carbapenems tested in our institutions
(i.e., ertapenem, imipenem, or meropenem) were considered as
carbapenem-resistant.
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Demographic and clinical characteristics of study population (N = 213).
Patient features n %
Healthcare organization of admission
Hospital A 139 65.26
Hospital B 30 14.08
Hospital C 44 20.66





Charlson index score; median (IQR) 2 (1–3)
Solid malignancy 31 14.55
Chronic renal failure 21 9.86
Diabetes 19 8.92
Hematologic malignancy 18 8.45
Solid organ transplantation 7 3.29
Length of hospital stay before onset of
BSI (days); median (IQR)
22 (11–37)
Ward of onset of BSI
Intensive Care Units 100 46.95
Medical wards 73 34.27
Surgical wards 27 12.68
Rehabilitation wards 13 6.10
Healthcare interventions before onset of BSI
Indwelling central venous catheter 155 72.77
Surgical intervention 101 47.42
Mechanical ventilation 77 36.15
Septic shock at presentation of BSI 42 19.72
Antimicrobial resistance pattern of isolated CR-Kpa
Colistin resistant 83 38.97
Gentamicin resistant 119 55.87
Tigecycline resistant 55 25.82
Initial antibiotic treatment
Adequate initial antibiotic therapy 43 20.19
Post-susceptibility test therapiesb
Monotherapy 13 6.91
Combined therapy 135 71.81
Combined therapy including a
carbapenem
123 65.43















15-Days mortality 56 26.29
a
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tatistical analysis
The incidence of CR-Kp BSI with its 95% confidence intervals
95% CI) was calculated as the number of events per 10,000 patient-
ays.
Characteristics of patients are presented with absolute frequen-
ies and percentages for categorical variables, and with median and
nterquartile range (IQR) for continue variables. Data were com-
ared between hospital with and without IDCs, by means of the
hi-square test, the Fisher exact test, or the Kruskal–Wallis test, as
ppropriate. All tests were two-sided, and a p value less than 0.05
as considered as statistically significant.
To identify risk factors associated with 15-day mortality in
he entire study population, a univariable statistic was  generated
y using the same tests mentioned above, as appropriate. Then,
ll demographic and clinical covariates associated with 15-day
ortality in univariable comparisons (p < 0.10) were included in
 stepwise backward multivariable model. All statistical analyses
ere performed with STATA SE14 (StataCorp, Texas, USA).
esults
From January 2013 to December 2014, we observed 213
pisodes of healthcare-associated CR-Kp BSI. Of them, 139 (65.3%)
ccurred at hospital A, 30 (14.1%) at hospital B, and 44 (20.6%) at
ospital C. The incidence of healthcare-associated CR-Kp BSI in the
ntire study population was 1.35 episodes per 10,000 patient-days,
ivided in 1.5 episodes per 10,000 patient-days at hospital A, 1.0
er 10,000 patient-days at hospital B, and 1.2 episodes per 10,000
atient-days at hospital C. Substantial difference in the incidence
f CR-Kp were observed between hospital A and the other two
ospitals (p = 0.02).
The complete demographic and clinical characteristics of the
ntire study population are summarized in Table 1, while Table 2
hows the data in hospitals with and without internal IDCs (the
haracteristics of patients with CR-Kp BSI in the different hospi-
als are detailed in Table S1). As shown in Table 2, a higher rate
f patients with hematological malignancies was  observed in the
ospitals with internal IDCs (hospitals A and B) rather than in hos-
ital C (11% vs. 0%, p = 0.03), while patients admitted at hospital
 had a higher median Charlson score (3 vs. 2, p = 0.03). Patients
dmitted to the two hospitals with internal IDCs were also more
ikely to have a CVC at the time of infection (80% vs. 43%, p < 0.001),
nd septic shock at BSI presentation (22% vs. 9%, p = 0.032). In con-
rast, higher rates of CR-Kp BSI occurring in the intensive care
nit (ICU) ward (64% vs. 43%, p = 0.002) and of patients receiving
echanical ventilation (50% vs. 33%, p = 0.036) were observed in
ospital C. With regard to antimicrobial therapy, patients admit-
ed to the two hospital with internal IDCs were more likely to
eceive post-susceptibility test combined therapies (82% vs. 38%,
 < 0.001), post-susceptibility test combined therapy including car-
apenems (77% vs. 26%, p < 0.001), adequate post-susceptibility test
herapies (88% vs. 52%, p < 0.001), and post-susceptibility thera-
ies prescribed by an infectious diseases specialist (84% vs. 14%,
 < 0.001). Of note, 86.7% of post-susceptibility test therapy pre-
cribed by IDCs were combined regimens including at least one
arbapenem. Interestingly, also the antimicrobial pattern of isolates
as very different. CR-Kp in hospital C was indeed less likely to be
olistin-resistant (25% vs. 42%, p = 0.033), gentamicin-resistant (32%
s. 62%, p < 0.001), and tigecycline-resistant (29% vs. 13%, p = 0.04)
han those in hospitals A and B.Please cite this article in press as: Cristina ML,  et al. Epidemiolo
siella pneumoniae bloodstream infections in hospitals within the sa
http://dx.doi.org/10.1016/j.jiph.2017.06.003
Overall, the crude 15-days mortality was 26%. Univariable and
ultivariable analyses of risk factors associated with mortality
re shown in Table 3. In univariable analysis, non-survivors were
ore likely to have solid malignancy, be exposed to mechanicalFor the analysis, strains with intermediate susceptibility to gentamicin and tyge-
cicline were considered as resistant.
b Calculated only for survivors at the time of post-susceptibility test results.
ventilation, have a septic shock at clinical presentation, and
receive post-susceptibility test therapy without carbapenems. In
contrast, mortality was  lower in patients with adequate initial
therapy and patients with post-susceptibility test combined
therapy including a carbapenem. In the final multivariable model,
only septic shock at BSI presentation remained unfavorably and
independently associated with 15-days mortality (odds ratio
[OR] 6.7, 95% CI 2.6–17.6, p < 0.001), while a protective effect was
observed for post-susceptibility test combined therapies including
a carbapenem (OR 0.11, 95% CI 0.03–0.43, p = 0.002).
Discussiongy, management, and outcome of carbapenem-resistant Kleb-
me endemic metropolitan area. J Infect Public Health (2017),
CR-Kp has been increasingly reported in Italy during the last two
decades, and unfortunately remain endemic [4,5,8,9]. The incidence
of 1.35 CR-Kp BSI episodes per 10,000 patient-days reported in the
present study is indeed in line both with our previous experience
ARTICLE IN PRESSG ModelJIPH-753; No. of Pages 7
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Table  2
Demographic and clinical characteristics of the patients admitted in hospitals with and without internal infectious diseases consultants.







Age (years); median (IQR) 72 (61–78) 69.5 (55–79.5) 0.59
Gender
Male  115/169 (68.05) 24/44 (54.55) 0.63
Female 54/169 (31.95) 20/44 (45.45)
Comorbidities
Charlson index score; median (IQR) 2 (1–3) 3 (1–3) 0.03
Solid  malignancy 26/169 (15.38) 5/44 (11.36) 0.50
Chronic renal failure 18/169 (10.65) 3/44 (6.82) 0.45
Diabetes 18/169 (10.65) 1/44 (2.27) 0.13
Hematological malignancy 18/169 (10.65) 0/44 (0) 0.03
Solid  organ transplantation 5/169 (2.96) 2/44 (4.55) 0.64
Length of hospital stay before onset of BSI (days); median (IQR) 23 (12–38) 17 (9.5–32) 0.11
Ward of onset of BSI 0.002
Intensive Care Units 72/169 (42.60) 28/44 (63.64)
Medical wards 61/169 (36.09) 12/44 (27.27)
Surgical wards 27/169 (15.98) 0 (0)
Rehabilitation wards 9/169 (5.33) 4/44 (9.09)
Healthcare interventions before onset of BSI
Indwelling central venous catheter 136/169 (80.47) 19/44 (43.18) <0.001
Surgical intervention 78/169 (46.15) 23/44 (52.27) 0.50
Mechanical ventilation 55/169 (32.54) 22/44 (50.00) 0.036
Septic shock at presentation of BSI 38/169 (22.49) 4/44 (9.09) 0.032
Antimicrobial resistance pattern of CR-Kp isolatesa
Colistin resistant 72/169 (42.60) 11/44 (25.00) 0.033
Gentamicin resistant 105/169 (62.13) 14/44 (31.82) <0.001
Tigecycline resistant 49/169 (28.99) 6/44 (13.64) 0.04
Initial antibiotic treatment
Adequate initial antibiotic therapy 32/169 (18.93) 11/44 (25.00) 0.37
Post-susceptibility test therapyb
Monotherapy 7/146 (4.79) 6/42 (14.29) 0.08
Combined therapy 119/146 (81.51) 16/42 (38.10) <0.001
Combined therapy including a carbapenem 112/146 (76.71) 11/42 (26.19) <0.001
Combined therapy including two carbapenem 11/146 (7.53) 2/42 (4.76) 0.53
Combined therapy without carbapenems 7/146 (4.79) 5/42 (11.90) 0.14
Combined therapy including colistin and rifampin 3/146 (2.05) 1/42 (2.38) 0.89
Adequate post-susceptibility test therapy 128/146 (87.67) 22/42 (52.38) <0.001
Post-susceptibility test therapy prescribed by ID consultants 122/146 (83.56) 6/42 (14.29) <0.001
Outcome



























a For the analysis, strains with intermediate susceptibility to gentamicin and tige
b Calculated only for survivors at the time of post-susceptibility test results. Al
ccording to study definitions.
n hospital A and with other surveys in our country [4,22,23]. How-
ver, we also detected some differences between centers, with a
ignificantly higher incidence being observed in the largest (hospi-
al A). Although such differences are possibly related to the higher
umber of ICU-beds in hospital A (critically-ill patients in ICU are
t increased risk of developing CRKP BSI [24]), we  think our anal-
sis highlight a possible heterogeneity of CR-Kp diffusion not only
etween countries and regions [25,26], but also within the same
ndemic metropolitan area. In turn, this stresses the need of a
trict coordination between neighboring facilities (e.g., providing
omplete information on proven/possible colonization of trans-
erred patient, sharing mutually recognized contention protocols),
o avoid the unwilled introduction of undetected carriers in those
enters still partially spared from an extensive CR-Kp diffusion.
In this study, we also explored the characteristics and the out-
ome of CR-Kp BSI in the different hospitals within the metropolitan
rea of Genoa. Several multicenter observational studies have
lready investigated these issues in patients with CR-Kp BSI
8,10–14,18]. In endemic areas such as Italy and Greece, CR-Kp
SI mostly occur among patients with multiple comorbidities,
eutropenia, indwelling devices, recent surgery, and previous hos-Please cite this article in press as: Cristina ML,  et al. Epidemiolo
siella pneumoniae bloodstream infections in hospitals within the sa
http://dx.doi.org/10.1016/j.jiph.2017.06.003
italizations [10,17]. As regards antimicrobial therapy, an increased
urvival has been reported in patients treated with combined ther-
pies paradoxically including carbapenems, although randomizede were considered as resistant.
-susceptibility tests were based on susceptibility test results and were adequate
clinical trials definitely assessing the validity of this approach have
still to be completed [17,18,27,28]. Keeping in mind this impor-
tant lack of high-level evidence, it is nonetheless worth noting
that PK/PD studies have suggested that high-dose meropenem
might retain bactericidal serum concentrations against some CR-
Kp strains, as a possible explanation for the survival benefit
reported in observational studies [12,29]. Against this complex
background, the role of the IDCs might be critical. Indeed, expertise
with dedicated and constant update is needed to balance benefits
(administration of an active therapy on the basis of patients’ isolates
and local antimicrobial epidemiology, appropriate dosages, escala-
tion and de-escalation approaches) and costs (toxicities, selection
of resistant strains) of the different therapeutic approaches in every
single case, and to identify as soon as possible the most appropriate
therapy to be administered [30–32].
In this study, a significantly higher rate of adequate post sus-
ceptibility test therapies was observed in the two hospitals with
internal IDCs than in that without (86% vs. 52%), with an even
higher difference being observed in the overall amount of thera-
pies prescribed by IDCs (86% vs. 14%). This result is in line with the
increase in appropriateness of prescriptions following ICs alreadygy, management, and outcome of carbapenem-resistant Kleb-
me endemic metropolitan area. J Infect Public Health (2017),
reported by different studies [33–36]. Consistently, most of IDCs
prescriptions in our study were combined therapy including car-
bapenems, which in turn were associated with increased survival.
ARTICLE IN PRESSG ModelJIPH-753; No. of Pages 7
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Table  3
Association between 15-days mortality and potential independent variables: results of univariate and multivariate logistic regression.





p-Value Odds ratio (CI 95%) p-Value





Female 55/158 (34.8) 19/56 (33.9)
Comorbidities
Charlson index score; median 2 (1–3) 2 (1–3.5) 0.13
Solid  malignancy 18/157 (11.46) 13/56 (23.21) 0.046
Chronic renal failure 16/157 (10.19) 5/56 (8.93) 0.79
Diabetes 16/157 (10.19) 3/56 (5.36) 0.41
Hematologic malignancy 11/157 (7.01) 7/56 (12.50) 0.26
Solid  organ transplantation 7/157 (4.46) 0/56 (0) 0.19
Length of hospital stay before onset of BSI (days); median (IQR) 20 (10–36) 24.5 (15–37.5) 0.25
Ward  of onset of BSI 0.67
Intensive Care Units 76/157 (48.41) 24/56 (42.86)
Medical wards 50/157 (31.85) 23/56 (41.07)
Surgical wards 21/157 (13.38) 6/56 (10.71)
Rehabilitation wards 10/157 (6.37) 3/56 (5.36)
Healthcare interventions before onset of BSI
Indwelling central venous catheter 114/157
(72.61)
41/56 (73.21) 0.93
Surgical intervention 78/157 (49.68) 23/56 (41.07) 0.28
Mechanical ventilation 50/157 (31.85) 27/56 (48.21) 0.03
Septic shock at presentation of BSI 19/157 (12.10) 23/56 (41.07) <0.001 6.70 (2.55–17.59) <0.001
Antimicrobial resistance pattern of isolated CR-Kpa
Colistin resistant 65/157 (41.40) 18/56 (32.14) 0.26
Gentamicin intermediate or resistant 88/157 (56.05) 31/56 (55.36) 0.96
Tigecycline intermediate or resistant 42/157 (26.75) 13/56 (23.21) 0.69
Initial antibiotic treatment
Adequate initial antibiotic therapy 38/157 (24.20) 5/56 (8.93) 0.02
Post-susceptibility test therapiesb




Combined therapy including a carbapenem 107/157
(68.15)
16/31 (51.61) 0.08 0.11 (0.03–0.43) 0.002
Combined therapy including two carbapenem 10/157 (6.37) 3/31 (9.68) 0.45
Combined therapy without carbapenems 6/157 (3.82) 6/31 (19.35) 0.001
Combined therapy including colistin and rifampin 2/157 (1.27) 2/31 (6.45) 0.13
Adequate post-susceptibility test therapy 123/157
(78.34)
25/31 (80.65) 0.77
Post-susceptibility test therapy prescribed by ID consultants 110/157
(70.06)
18/31 (58.06) 0.21
Hospitals with internal ID consultations 120/157
(71.01)
49/56 (28.99) 0.08






















b Calculated only for survivors at the time of post-susceptibility test results. Al
ccording to study definitions.
c Only variables selected through stepwise approach and included in the final mu
owever, consultations themselves were apparently not associ-
ted with increased survival. These conflicting results could be
xplained by the fact that we were able to retrieve only IDCs pre-
criptions following susceptibility test results, while the overall
ffect of carbapenem-based regimens on the outcome was con-
eivably also related to those adequate therapies administered
mpirically, pending blood cultures results. In this regard, it should
e noted that rates of adequate initial therapy were worryingly
ow in the entire study population, irrespective of the presence
f internal IDCs. In our opinion, this result highlights the neces-
ity of improving collaboration between ward physicians and IDCs.
ndeed, consultations should be requested as soon as CR-Kp col-
nized patients develop signs and symptoms of infection and not
fter susceptibility test results, in view of the well-known favorablePlease cite this article in press as: Cristina ML,  et al. Epidemiolo
siella pneumoniae bloodstream infections in hospitals within the sa
http://dx.doi.org/10.1016/j.jiph.2017.06.003
ffect on survival of an adequate empiric therapy [30,31,37]. In this
ight, major efforts have been recently made to implement dedi-
ated antimicrobial stewardship programs in our hospitals, with
lso the aim of increasing the number of early IDCs.-susceptibility tests were based on susceptibility test results and were adequate
iate model are presented.
Finally, the present study confirmed the already well-known
association between septic shock and mortality of CR-Kp BSI
[17,18]. Of note, the percentage of patients presenting with septic
shock was very low in hospital C, possibly explaining why mortal-
ity was  not different from that of the other hospitals despite lower
rates of IDCs and adequate therapies.
This study has some important drawbacks. First, it was retro-
spective, and under-reporting might have occurred in some cases.
Second, as reported above, we  were not able to collect data about
IDCs for prescribing empirical therapies, since we  did not have
complete information regarding early telephone consultations. In
view of their possible favorable impact on the outcome of CR-Kp
BSI, we  think they role deserves further dedicated investigation.
Another limitation is the lack of information on possible con-gy, management, and outcome of carbapenem-resistant Kleb-
me endemic metropolitan area. J Infect Public Health (2017),
comitant infections due to other organisms, that might have also
influenced the outcomes in some cases. Finally, from an epidemi-
ological standpoint, an important limitation is the lack of more

















































ARTICLEIPH-753; No. of Pages 7
 M.L. Cristina et al. / Journal of Infect
ossible differences in the clonal types of CR-Kp and their mecha-
isms of resistance to carbapenems in the different centers.
In conclusion, mortality of CR-Kp remains high. Differences in
he incidence of CR-Kp BSI were detected between acute-care cen-
ers within the same endemic metropolitan area. Efforts should
e made to improve the collaboration and coordination between
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